Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03580382
Title Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors New York University School of Medicine
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
New York University School of Medicine New York New York 10016 United States Details
Thomas Jefferson University Philadelphia Pennsylvania 19107 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field